Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

900 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antimicrobial surveillance: A 20-year history of the SMART approach to addressing global antimicrobial resistance into the future.
Cantón R, Gottlieb T, Coombs GW, Woo PCY, Korman TM, Garcia-Castillo M, Daley D, Bauer KA, Wong M, Wolf DJ, Siddiqui F, Motyl M. Cantón R, et al. Among authors: siddiqui f. Int J Antimicrob Agents. 2023 Dec;62(6):107014. doi: 10.1016/j.ijantimicag.2023.107014. Epub 2023 Oct 21. Int J Antimicrob Agents. 2023. PMID: 37866472 Free article.
In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
Lob SH, Kazmierczak KM, Chen WT, Siddiqui F, DeRyke CA, Young K, Motyl MR, Sahm DF. Lob SH, et al. Among authors: siddiqui f. J Glob Antimicrob Resist. 2022 Jun;29:527-533. doi: 10.1016/j.jgar.2021.11.011. Epub 2021 Dec 8. J Glob Antimicrob Resist. 2022. PMID: 34896336 Free article.
In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020.
Karlowsky JA, Lob SH, DeRyke CA, Hilbert DW, Wong MT, Young K, Siddiqui F, Motyl MR, Sahm DF. Karlowsky JA, et al. Among authors: siddiqui f. Antimicrob Agents Chemother. 2022 May 17;66(5):e0018922. doi: 10.1128/aac.00189-22. Epub 2022 May 2. Antimicrob Agents Chemother. 2022. PMID: 35491836 Free PMC article.
Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020.
Lob SH, Estabrook MA, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF. Lob SH, et al. Among authors: siddiqui f. Int J Infect Dis. 2022 Dec;125:250-257. doi: 10.1016/j.ijid.2022.10.014. Epub 2022 Oct 14. Int J Infect Dis. 2022. PMID: 36244599 Free article.
In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with lower respiratory tract infections in Western Europe: SMART 2018-20.
Karlowsky JA, Lob SH, Akrich B, DeRyke CA, Siddiqui F, Young K, Motyl MR, Hawser SP, Sahm DF. Karlowsky JA, et al. Among authors: siddiqui f. JAC Antimicrob Resist. 2023 Jan 20;5(1):dlad003. doi: 10.1093/jacamr/dlad003. eCollection 2023 Feb. JAC Antimicrob Resist. 2023. PMID: 36694850 Free PMC article.
In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.
Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF. Karlowsky JA, et al. Among authors: siddiqui f. J Med Microbiol. 2023 Feb;72(2). doi: 10.1099/jmm.0.001645. J Med Microbiol. 2023. PMID: 36763081
900 results